若生智能
Drug Database
OX

oxybutynin hydrochloride (HP 5070 / HP5070 / Apohide)

✓ Approved

Hisamitsu · 小分子 · 小分子

什么是 oxybutynin hydrochloride？

oxybutynin hydrochloride 是一种小分子，由Hisamitsu研发。该药已获批，用于治疗相关适应症，给药途径：Topical、Transdermal。

药物档案

商品名HP 5070, HP5070, Apohide
公司Hisamitsu
药物类别小分子
给药途径Topical, Transdermal
状态Approved
来源： ClinicalTrials.gov, Hisamitsu

治疗适应症

oxybutynin hydrochloride 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersHyperhidrosis✓ Approved

相关研究文献

PubMedBMJ open2026-06-13

Minocycline hydrochloride ointment-assisted periodontal treatment of stage III/IV periodontitis associated with type 2 diabetes mellitus targeting Chinese people: study protocol for a randomised controlled trial.

Zhao Hongqiao H, Lin Sichi S, He Lu L, Zhen Min M et al.

Scaling and root planing (SRP) combined with adjunctive antibiotic therapy is widely adopted in the management of periodontitis in patients with type 2 diabetes mellitus (T2DM), with the aims of ameliorating glycaemic control, alleviating local inflammation and facilitating periodontal tissue regeneration. As a topically administered adjunctive antibiotic for periodontal treatment, minocycline hydrochloride (MH) ointment has shown favourable clinical efficacy in systemically healthy patients with periodontitis. However, robust evidence supporting its clinical efficacy and potential glycaemic-improving effects in patients with periodontitis complicated by T2DM remains limited. The present study is designed to test the null hypothesis that no significant differences in clinical outcomes exist between SRP combined with MH and SRP alone in the management of periodontitis among patients with T2DM, with its primary objective to investigate whether MH as an SRP adjunct confers superior clinical benefits to SRP alone. We will conduct a randomised, single-blind, placebo-controlled clinical trial. 56 patients with T2DM-associated stage III/IV periodontitis will be recruited from the Department of Periodontology, Peking University School and Hospital of Stomatology, Beijing, China. Eligible participants will be randomised into two groups: the experimental group will undergo SRP combined with topically administered MH ointment and the control group will undergo SRP with a matched placebo. The primary outcomes will include probing depth (PD) changes at periodontal pocket sites with a baseline PD ≥6 mm at 6 months post-baseline, with a specific focus on the percentage of such sites with PD reduced to ≤5 mm. The secondary outcomes will comprise PD changes at pocket sites with a baseline PD ≥5 mm at 6 months post-baseline, as well as clinical attachment loss, the plaque index, bleeding index, the levels of IL-1β, IL-17, calprotectin and insulin levels in gingival crevicular fluid and serum, complete blood count, blood biochemistry, including glycated haemoglobin levels, and the composition of subgingival plaques at baseline, and 2 and 6 months post-baseline. This study was approved by the Ethics Committee of Peking University School and Hospital of Stomatology (PKUSSIRB-2024102139b). Results will be published in a peer-reviewed scientific journal. ChiCTR2400092305. V.3.1 (date: 6 January 2026).

PMID 42285579
阅读全文 →
PubMedCarbohydrate polymers2026-06-13

In situ NMR investigation of the native chemical ligation (NCL) of N-terminal cysteines to alginate.

Bučak Gasser David D, Steindorfer Tobias T, Neshchadin Dmytro D, Gescheidt Georg G et al.

Polysaccharide-peptide conjugates constitute an important class of biomaterials for tissue engineering scaffolds and glycoconjugate vaccines. Yet, benign and chemoselective synthetic strategies that operate under aqueous, physiologically relevant conditions remain scarce. Herein, we present a proof-of-concept approach for the traceless conjugation of N-terminal l-cysteines to alginate. A glycine-derived thioester functionality was synthesized and covalently introduced onto the uronic acid residues of alginate (DS = 0.47), as confirmed by 1H and 13C NMR and ATR-IR spectroscopy. The resulting alginate-thioester derivative served as a hydrolytically stable and chemoselective reactive handle for the native chemical ligation (NCL) of l-cysteine hydrochloride (l-cys·HCl) and the dipeptide l-cysteinylglycine (l-cys-gly). The ligation reactions were monitored in situ by kinetic 1H NMR spectroscopy. Control experiments of the alginate-thioester derivative with alternative biological nucleophiles glycine and l-lysine showed no reactivity (1H NMR), thus confirming the selectivity toward the thiol functionality of N-terminal l-cysteines under the provided conditions (0.1 M PO43- buffer, pH 7, 25 °C). This work establishes a convenient aqueous method to prepare peptide-polysaccharide conjugates in which the peptide is linked to the polysaccharide exclusively through stable amide bonds, without the incorporation of exogenous linker molecules or the use of conventional coupling agents or protecting groups.

PMID 42285655
阅读全文 →
PubMedMaterials (Basel, Switzerland)2026-06-12

Facile Preparation of a Plasmon-Enhanced Ag-CuO/TiO2 for the Efficient Visible-Light-Driven Photodegradation of Tetracycline Hydrochloride.

Cui Lianmin L, Ren Li L, Chen Zhi Z, Zhu Benfeng B et al.

Water pollution caused by antibiotics is a growing problem. Therefore, photodegradation by efficient catalysts is an environmentally friendly technology that can effectively degrade organic pollutants in water. In this work, a method was innovatively used to prepare a ternary heterostructure of plasmon-enhanced Ag-CuO/TiO2. The composite was synthesized through a facile stepwise strategy involving the formation of CuO nanorods, TiO2 coating, and subsequent deposition of Ag nanoparticles on their surface using AgNO3, enabling intimate interfacial contact among the different components. The prepared samples were characterized by XRD, HRTEM, XPS, and UV-Vis. The chemical composition of the composite Ag-CuO/TiO2 showed a Cu/Ti atomic ratio of 2.58, as well as a Ag/Cu ratio of 0.91. The UV-Vis spectrum reveals the largest absorption peak at 550 nm for the composite Ag-CuO/TiO2. The prepared Ag-CuO/TiO2 composites were applied to the visible-light degradation of tetracycline hydrochloride, with the photocatalytic degradation rate reaching 80.7% under the optimal conditions within 60 min, which is significantly better than CuO and CuO/TiO2 without silver nanoparticles. Capture experiments indicated that h+ are involved during the course of the photodegradation and that h+ are the main active substances. Furthermore, the proposed mechanism for the photodegradation of the Ag-CuO/TiO2 composites is given. It has potential applications in the treatment of organic pollutants in water.

PMID 42279842
阅读全文 →
PubMedMaterials (Basel, Switzerland)2026-06-12

Revealing the pH-Dependent Adsorption Dynamics of Tetracycline Hydrochloride on Phosphoric Acid-Activated Corncob Biochar.

Zhao Qiang Q, Zhao Gaotian G, Zhang Yalei Y, Yan Yangyang Y et al.

Aquaculture wastewater containing tetracycline hydrochloride (TCH) poses significant environmental problems and health risks. We investigated the adsorption of TCH onto phosphoric acid-activated corncob biochar (PCC) as a sustainable and efficient removal strategy. PCC was synthesized from cob feedstock activated by phosphoric acid under a pyrolysis temperature of 300 °C in a limited-air atmosphere. It was characterized extensively, revealing a high specific surface area (1071.75 m2/g), high porosity with total pore volume of 0.912 cm3/g, and abundant surface functional groups including phosphate, carboxylic, and amine groups. Batch adsorption experiments demonstrated an ultrahigh adsorption capacity for TCH, with a maximum theoretical capacity (Langmuir model) of 953.62 mg/g at 313 K. Its adsorption isotherms transfer from Langmuir type to Freundlich type as temperature rises, indicating a transition from monolayer to multilayer adsorption. The adsorption kinetics were governed by a synergistic mechanism involving surface adsorption and a pore-filling effect (intra-particle diffusion). Critically, the adsorption dynamics exhibit an intra-particle diffusion-controlled process at a low pH (3.0) during the final stage of adsorption. Strong hydrogen bonding led to high initial adsorption rates, and the adsorption converted to diffusion-controlled mode eventually. In contrast, at higher pH (≥7.0), electrostatic repulsion between PCC adsorbents and TCH molecules hindered intra-particle diffusion, causing the final adsorption stage to deviate from diffusion control. This work provides comprehensive insights into the pH-dependent interfacial interactions and kinetics governing TCH removal by corncob-derived, phosphoric acid-activated biochar.

PMID 42279913
阅读全文 →
PubMedJournal of Asian natural products research2026-06-12

Suaeglaucin C: a new coumaronochromone isolated from Suaeda glauca.

Jia Jia J, Ding Xian-Rui XR, Zang Xiao-Han XH, Fang Ying-Jun YJ et al.

A new coumaronochromone (1), and 12 known compounds (2-13) were isolated from the ethyl acetate part of an aqueous EtOH extract of Suaeda glauca. Compounds 5-8 and 12 effectively ameliorated pericardial edema and venous congestion in zebrafish embryos induced by verapamil hydrochloride at 50 μM. Among these, 8 exhibited superior efficacy in reducing pericardial edema compared to the positive control, Digoxin. In contrast, 1-3 displayed significant lethality in zebrafish embryos, with LC50 values of 9.41, 39.59, and 24.47 μM, respectively. Furthermore, these three compounds showed potential cytotoxic effects on HCT116 cells at 30 and 50 μM.

PMID 42283297
阅读全文 →
PubMedBMC neurology2026-06-12

Clazosentan in aneurysmal subarachnoid hemorrhage: an updated systematic review and meta-analysis of efficacy and safety.

Alsakti Abdulelah Mohammed AM, Ghazwi Zahra Hassan Al ZHA, AlOtaibi Abdulrahman Khalid AK, Alharbi Mohammed Abdullah MA et al.

Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening neurological condition associated with high morbidity and mortality. Delayed cerebral ischemia (DCI), largely driven by cerebral vasospasm, remains a major determinant of poor outcomes. Clazosentan, a selective endothelin A receptor antagonist, reduces vasospasm, but its impact on clinical outcomes remains uncertain. This study aimed to evaluate its association with vasospasm-related and clinical outcomes, and its safety profile. This systematic review and meta-analysis followed PRISMA guidelines. PubMed, Cochrane Library, and Google Scholar were searched through March 2026. Outcomes included vasospasm, cerebral infarction, DINDs, functional outcomes, mortality, and adverse events. Random-effects models (DerSimonian-Laird estimator) were applied, and predefined subgroup analyses were performed by clazosentan dose, comparator type (placebo vs. fasudil hydrochloride), aneurysm treatment modality, and study design (randomized controlled trials (RCTs) vs. observational cohort studies). Certainty of evidence for each outcome was rated using the GRADE framework, with RCT and cohort evidence rated as separate bodies of evidence. Sixteen studies (17 reports; 7 RCTs comparing clazosentan with placebo and 9 cohort studies comparing clazosentan with fasudil hydrochloride) were included. In RCTs clazosentan was associated with statistically significant reductions in angiographic vasospasm and rescue-therapy use (high GRADE certainty), and in vasospasm-related cerebral infarction and DINDs (moderate certainty, downgraded for publication bias). In pooled observational data versus fasudil hydrochloride, directionally concordant reductions were observed for angiographic vasospasm (low certainty) and vasospasm-related infarction (very low certainty), but no statistically significant differences were observed for DINDs or rescue therapy. However, no statistically significant differences were observed in functional outcomes or mortality in either body of evidence (moderate certainty for poor functional outcome and mortality in RCTs; very low certainty for favourable functional outcome and mortality in cohort studies). Larger effect estimates were observed with 10-15 mg doses in aggregate study-level analyses; because dose was assigned at the study level rather than randomized within patients, these gradients are descriptive rather than confirmatory of a within-patient dose-response relationship. Study design-stratified analysis showed concordant reductions in vasospasm and cerebral infarction across RCTs and cohorts, while effects on DINDs, rescue therapy, and hypotension reached significance only in RCTs. Clazosentan was associated with increased risks of anemia, hypotension, pleural effusion, pulmonary edema, and pneumonia, with no statistically significant difference in cerebral hemorrhage. Across both bodies of evidence, clazosentan was associated with statistically significant reductions in angiographic vasospasm and vasospasm-related ischemic complications in aSAH, but these surrogate gains did not translate into statistically significant improvements in survival or functional recovery in either randomized or observational evidence, and were accompanied by clinically relevant increases in anemia, hypotension, and pulmonary complications. Observational comparisons with fasudil are at serious-to-critical risk of confounding by indication, treatment selection, and temporal changes in care, and should be considered hypothesis-generating. Because demonstrable improvement in patient-centered endpoints (survival, functional recovery) has not been shown, Routine use is not supported by current evidence; any role for clazosentan is likely limited to selected high-risk patients in whom the anticipated reduction in ischemic complications is explicitly judged to outweigh the systemic harm.

PMID 42277709
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多oxybutynin hydrochloride